An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on May 1, 2024, to discuss the financial results for the first quarter 2024, revenue guidance for the second quarter, and financial outlook for the full year. Participants can join via webcast or telephone by registering in advance.
Emergent BioSolutions Inc. (NYSE: EBS) organizzerà una teleconferenza il 1 maggio 2024 per discutere i risultati finanziari del primo trimestre del 2024, le previsioni di fatturato per il secondo trimestre e le prospettive finanziarie per l'intero anno. I partecipanti possono unirsi tramite webcast o telefono previa registrazione.
Emergent BioSolutions Inc. (NYSE: EBS) celebrará una conferencia telefónica el 1 de mayo de 2024 para discutir los resultados financieros del primer trimestre de 2024, la guía de ingresos para el segundo trimestre y la perspectiva financiera para el año completo. Los participantes pueden unirse vía webcast o teléfono registrándose con antelación.
Emergent BioSolutions Inc. (NYSE: EBS)는 2024년 5월 1일에 2024년 1분기 재무 결과, 2분기 수익 가이던스 및 연간 재무 전망에 대해 논의하기 위해 컨퍼런스 콜을 개최할 예정입니다. 참가자는 사전 등록을 통해 웹캐스트 또는 전화로 참여할 수 있습니다.
Emergent BioSolutions Inc. (NYSE: EBS) organisera une conférence téléphonique le 1 mai 2024 pour discuter des résultats financiers du premier trimestre de 2024, des prévisions de revenus pour le deuxième trimestre et des perspectives financières pour l'année entière. Les participants peuvent rejoindre via webcast ou téléphone en s'inscrivant à l'avance.
Emergent BioSolutions Inc. (NYSE: EBS) wird am 1. Mai 2024 eine Telefonkonferenz veranstalten, um die Finanzergebnisse für das erste Quartal 2024, die Umsatzprognose für das zweite Quartal und die finanzielle Ausblick für das gesamte Jahr zu besprechen. Teilnehmer können sich per Webcast oder Telefon nach vorheriger Anmeldung beteiligen.
Positive
None.
Negative
None.
GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full year 2024.
Conference Call Information Participants can access the conference call live via webcast. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call.
A replay of the call can be accessed from the Investors page of Emergent’s website.
About Emergent BioSolutions At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact: Richard S. Lindahl Executive Vice President, CFO lindahlr@ebsi.com